# A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

> **NCT02640833** · PHASE1 · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Duvelisib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT02640833
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-07
- **Primary completion:** 2020-01
- **Final completion:** 2021-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study Stopped
- **Last updated:** 2016-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02640833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02640833, "A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02640833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*